

From: [Trials](#)
To: smaebius@foley.com; jmock@foley.com; [FOLEY AJINOMOTO IPR2025_0283](#); jason.engel.ptab@klgates.com; [Hill, Rebekah](#); [Giunta, Peter](#)
Cc: [Trials](#)
Subject: IPR2025-00283 briefing
Date: Monday, May 11, 2026 10:04:55 AM
Attachments: [image001.png](#)

This Message Is From an External Sender

This message came from outside your organization.

Counsel,

Petitioner and Patent Owner in IPR2025-00283 are invited (but not required) to file simultaneous supplemental letter briefs addressing the issue of whether the proposed substitute claims 14-16 of US Patent 11,896,657 meet the written description requirement under 35 U.S.C. § 112 in light of Teva Pharm. v. Eli Lilly & Co., 172 F.4th 1367 (Fed. Cir. 2026).

The briefs shall be filed within 14 days of the date of this communication. No reply briefs are authorized.

Regards,

Andrew Kellogg,
Deputy Chief Clerk, Trials
Patent Trial and Appeal Board
USPTO
andrew.kellogg@uspto.gov
(571) 272-5366

